Free Newsletter
Vanda sleep therapy rewinds your body clock
A study of 450 people given Vanda Pharmaceuticals' experimental sleep drug tasimelteon demonstrated that the therapy can swiftly reset a body's circadian rhythm, offering a potential new treatment for people who suffer from jet lag or the effects of a night shift schedule. The drug mimics the natural effect of melatonin, which regulates sleep patterns according to the amount of light and darkness an individual is exposed to.
The researchers at Brigham and Women's Hospital in Boston say the drug was effective at restoring regular sleep from the first night and could be used without the kind of potential for addiction and abuse that has plagued other sleep therapies. Patients taking the highest dose available in the study slept 428 minutes compared to an average of 324 minutes for volunteers taking a placebo.
"This is a very promising first step," Dr. Jay Udani, from the Northridge Hospital Medical Center, told the Los Angeles Times. But the research "does not prove that it works for jet lag or shift workers," he added. "That needs controlled studies in the field."
- see Vanda's release
- read the report from the Los Angeles Times
Related Articles:
Vanda Pharma cuts staff, halts development work
Vanda shares swoon after FDA rejects therapy
Vanda shares surge on Phase III insomnia data
Bad news at Vanda hurts stock prices
Vanda Pharmaceuticals - Worst Pharma Stocks of 2007
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


